Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7

a pyrimidine inhibitor and phosphodiesterase technology, applied in the field of pde7 pyrimidine inhibitors, can solve the problems of pde4 inhibitors being controversial and limited in their use, and achieving the effect of reducing the number of active enzymes in the body

Active Publication Date: 2006-04-04
BRISTOL MYERS SQUIBB CO
View PDF18 Cites 49 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0294]Those present compounds which are dual PDE7 / 4 inhibitors may be more effective than either a selective PDE4 inhibitor or a selective PDE7 inhibitor in the above mentioned disease states, as a result of either additive or synergistic activity resulting from the combined inhibition of PDE7 and PDE4.

Problems solved by technology

Such activity would represent an undesirable side effect in a therapeutic agent with the utilities listed in this patent for a PDE7 inhibitor.
Such activity would represent an undesirable side effect in a therapeutic agent with the utilities listed in this patent for a PDE7 inhibitor.
The utility of PDE4 inhibitors has been limited to some extent by their propensity to cause emesis.
Although abundant PDE7A2 mRNA has been identified, the presence of active enzyme in tissues is controversial, as no convincing data shows PDE7A2 protein in situ in the adult.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7
  • Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7
  • Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7

Examples

Experimental program
Comparison scheme
Effect test

example a1

2-[[6,7-Dimethoxy-4-[[[4-(methylsulfonyl)phenyl]methyl]amino]-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester

[0310]

A1.1: 2-Chloro-6,7-dimethoxy-4-(4-methylsulfonylbenzyl)quinazoline

[0311]

[0312]A mixture of commercially available 2,4-dichloro-6,7-dimethoxyquinazoline (200 mg, 0.772 mmol, 1 eq), 4-methylsulfonylbenzylamine hydrochloride (180 mg, 0.810 mmol, 1.05 eq) and diisopropylethylamine (0.40 mL, 2.32 mmol, 3 eq) in tetrahydrofuran (7.7 mL) was heated at reflux for 15.25 h. The reaction mixture was then cooled to rt and concentrated in vacuo. The resultant solid was slurried in methanol (10 mL) collected by filtration, washed with methanol and dried to provide 282 mg (89%) of A1.1 as an off-white solid. LC / MS: 408 [M+H]+; HPLC: 98% at 3.19 min (Phenomenex 5 μm C18 column 4.6×50 mm, 10–90% aqueous methanol over 4 min containing 0.2% phosphoric acid, 4 mL / min, monitoring at 254 nm); 1H NMR (400 MHz, DMSO-d6): δ 8.98 (m, 1 H), 7.91 (d, J=8.3 Hz, 2 H), 7.69 (s, ...

example a2 – a13

Example A2–A13

[0314]

[0315]Examples A2 to A13 were prepared in a similar manner to that used for Example A1 utilizing the appropriate amines in step A1.1.

[0316]

TABLE AHPLCRetentionMSEx.LName(min)ReportedA22-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]-6,7-dimethoxy-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylicacid, ethyl ester3.19559.08A32-[[4-[[(3,4-Dimethoxyphenyl)methyl]amino]-6,7-dimethoxy-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylicacid, ethyl ester3.36540.27A42-[[4-[[[4-[(Acetylamino)sulfonyl]phenyl]methyl]amino]-6,7-dimethoxy-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylicacid, ethyl ester3.33600.95A52-[[4-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-6,7-dimethoxy-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylicacid, ethyl ester3.75566.13A62-[[4-[[2-[4-(Aminosulfonyl)phenyl]ethyl]amino]-6,7-dimethoxy-2-quinazolinyl]amino]-4-methyl-5-thiazolecarboxylicacid, ethyl ester3.11573.38A72-[[6,7-Dimethoxy-4-[(3-pyridinylmethyl)amino]-2-quinazolinyl]amino]-4-methy...

example a14

2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]-6,7-dimethoxy-2-quinazolinyl]amino]-4-trifluoromethyl-5-thiazolecarboxylic acid, ethyl ester

[0317]

[0318]A14 was prepared in an manner analogous to example A1 with the exception that in step A1.1 4-aminosulfonylbenzylamine hydrochloride was substituted for 4-methylsulfonylbenzylamine hydrochloride, and in step A1.2 ethyl 2-amino-4-trifluoromethyl-5-thiazole carboxylate was substituted for ethyl 2-amino-4-methyl-5-thiazole carboxylate. LCMS=Ret. Time=1.61 min*, M+=613.20* HPLC conditions used to determine retention times; 2 min gradient 0–100% B in A(A; 0.1% TFA in 90 / 10 water / methanol; B; 0.1% TFA in 10 / 90 water / methanol) using a TMC turbopack column at 220 nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
total volumeaaaaaaaaaa
volumeaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Quinazoline and pyrido[2,3-d]pyrimidine phosphodiesterase 7 (PDE 7) inhibitors of the following formula wherein R1, R2, L, Y1, Y2, Y3 and Z are as described herein, are provided which are useful in treating T-cell mediated diseases.

Description

[0001]This application claims priority to U.S. Provisional Application Ser. No. 60 / 299,287 filed Jun. 19, 2001, and U.S. Provisional Application Ser. No. 60 / 368,752 filed Mar. 29, 2002. The entirety of each of these applications is incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase 7 (PDE 7) (including both selective inhibitors of PDE 7, and dual inhibitors of PDE 7 and phosphodiesterase 4), pharmaceutical compositions containing these inhibitors, and the use of these inhibitors in the treatment of leukocyte activation-associated or leukocyte-activation mediated disease and inflammatory diseases either alone or in combination with other therapeutic agents.BACKGROUND OF THE INVENTION[0003]Phosphodiesterases (PDEs) hydrolyze the second messenger molecules cAMP and cGMP to affect cellular signaling. At least 11 families of PDEs exist, some of which (PDE3,4,7,8) are specifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(United States)
IPC IPC(8): C07D237/02A01N43/58A61K31/50C07D239/95A61K31/00A61K31/505A61K31/506A61K31/513A61K31/517A61K31/519A61K31/52A61K31/522A61K31/5377A61K31/551A61K31/56A61K31/573A61K45/00A61P1/00A61P1/04A61P3/10A61P5/14A61P9/08A61P9/10A61P11/00A61P11/04A61P11/06A61P17/04A61P17/06A61P17/14A61P19/00A61P19/02A61P21/04A61P25/00A61P25/28A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00C07D401/12C07D403/12C07D417/12C07D417/14C07D471/04C07D473/00C07D473/16C07D487/04C07D491/10C07D498/10
CPCA61K31/00C07D491/10A61K31/506A61K31/513A61K31/517A61K31/519A61K31/522C07D401/12C07D403/12C07D417/12C07D417/14C07D471/04C07D473/00C07D473/16C07D487/04A61K31/505A61P1/00A61P1/04A61P11/00A61P11/04A61P11/06A61P17/04A61P17/06A61P17/14A61P19/00A61P19/02A61P21/04A61P25/00A61P25/28A61P29/00A61P35/00A61P37/00A61P37/02A61P37/06A61P43/00A61P5/14A61P9/08A61P9/10A61P3/10
Inventor PITTS, WILLIAM J.BARBOSA, JOSEPH
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap